GLUE Earnings & Financial Statements
Monte Rosa Therapeutics, Inc.
$10.12
+$0.28(+2.85%)
42
Overall
60
Value
36
Tech
31
Quality
Market Cap
$839.48M
Volume
1.54M
52W Range
$8.94 - $25.77
Target Price
$28.00
GLUE earnings and financial statements: Monte Rosa Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
GLUE Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $123.67M | $75.62M | - | - | - |
| Operating income | -$54.21M | -$81.11M | -$143.31M | -$112.38M | -$72.88M |
| EBITDA | -$44.31M | -$72.58M | -$128.59M | -$105.23M | -$71.85M |
| Net income | -$38.63M | -$72.70M | -$135.35M | -$108.50M | -$73.96M |
| EPS (diluted) | $-0.46 | $-0.98 | $-2.63 | $-2.30 | $-2.96 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $448.66M | $438.73M | $303.75M | $342.39M | $366.33M |
| Total liabilities | $215.60M | $215.80M | $124.50M | $70.98M | $18.81M |
| Shareholders’ equity | $233.06M | $222.94M | $179.25M | $271.41M | $347.51M |
| Cash and equivalents | $129.88M | $224.25M | $128.10M | $54.91M | $346.07M |
| Long-term debt | $34.79M | $39.00M | $42.88M | $43.87M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$22.80M | $42.00M | -$43.80M | -$92.47M | -$59.36M |
| Capital expenditure | -$4.70M | -$3.99M | -$19.04M | -$12.91M | -$9.73M |
| Free cash flow | -$27.50M | $38.01M | -$62.84M | -$105.38M | -$69.09M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GLUE | $10.12 | +2.8% | 1.54M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Monte Rosa Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW